CRISPR Therapeutics Hits Day Low of $48.77 Amid Price Pressure

CRISPR Therapeutics AG experienced significant volatility on April 24, 2026, with the stock declining by 11.59% and reaching an intraday low of USD 48.77. This performance starkly contrasts with the S&P 500, which saw a modest gain of 0.8% on the same day. Over the past week, CRISPR's stock has dropped 15.87%, while its one-month performance shows a slight increase of 5.07%, lagging behind the S&P 500's 9.28% gain. The company's financial metrics indicate ongoing challenges, with a return on equity (ROE) of just 3.15%, reflecting low profitability relative to shareholders' funds. Additionally, CRISPR has reported negative results for four consecutive quarters, with net sales plummeting by 95.17% to USD 1.75 million and an operating cash flow of -USD 345.01 million. With a market capitalization of USD 4,656 million, CRISPR Therapeutics operates within the pharmaceuticals and biotechnology sector. However, its performance over the past three years shows a decline of 4.49%, and a staggering 61.45% drop over the last five years, highlighting the stock's challenging market position.